Copy number variability analysis of pharmacogenes in patients with lymphoma, leukemia, hepatocellular, and lung carcinoma using the Cancer Genome Atlas data

Medicine and Dentistry

• Acute Myeloid Leukemia 66%
• Biological Marker 33%
• Cancer Tissue 33%
• Copy Number Variation 66%
• CYP2A6 33%
• CYP2E1 33%
• Diffuse Large B-Cell Lymphoma 100%
• Drug Efficacy 33%
• Drug Metabolizing Enzyme 33%
• Drug Response 33%
• Drug Toxicity 33%
• Gene Loss 33%
• Germ Cell 66%
• Hepatocellular Carcinoma 100%
• Leukemia 100%
• Lung Carcinoma 100%
• Neoplasm 33%
• Somatics 66%
• The Cancer Genome Atlas 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Acute Myeloid Leukemia 66%
• Biological Marker 33%
• CYP2A6 33%
• CYP2D6 33%
• CYP2E1 33%
• Diffuse Large B Cell Lymphoma 100%
• Drug Metabolizing Enzyme 33%
• Leukemia 100%
• Liver Cell Carcinoma 100%
• Lung Carcinoma 100%
• Neoplasm 33%
• Squamous Cell Lung Carcinoma 100%

Biochemistry, Genetics and Molecular Biology

• B Cell 100%
• Copy-Number Variation 66%
• CYP2A6 33%
• CYP2D6 33%
• CYP2E1 33%
• Drug Efficacy 33%
• Drug Response 33%
• Drug Toxicity 33%
• Enzyme 33%
• FHIT 33%
• Gene Loss 33%
• Germ Cell 66%
• GSTP1 33%
• GSTT1 33%
• Myeloid 66%
• P2RY1 33%
• SLC19A1 33%
• SULT1A1 33%